Indeed, the bio-available Prmt1 inhibitors AMI-40858,59 (Supplementary Fig. 8c) and TC-E 5003 achieved a 50–60% reduction in tumor burden (Fig. 8c) accompanied by a decrease in Ki67+ proliferative cells after 2 weeks of treatment in a syngeneic orthotopic model of PDAC (Fig. 8d). The gene discussed is PRMT1; the disease is neoplasm.